Study Condition(s): Type 2 Diabetes

A Study of U-500 Insulin (Humulin LY041001) in Participants With Type 2 Diabetes

Study Alias: IBHG

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02588950 {{ currentLocaleObject.registryAnchorText }}

Terminated Terminated

Study Purpose

The purpose of this study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.

Terminated Study

This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study

Gender

Male Female

Age

18 years
74 years

Time Commitment

Your participation could last from 7 to 14 weeks and include 5 visits to the study center
  • Participant must have type 2 diabetes mellitus (T2DM)

  • Participant must be currently using U-100 insulin analog with a total daily dose of greater than 200 units and have a total daily dose of less than or equal to 3.0 units per kilogram; basal; premixed; or basal/bolus by any injection device

  • Participant must be on concomitant antihyperglycemic agent(s) which may include metformin (MET), dipeptidyl peptidase 4 inhibitors, pioglitazone, glucagon like peptide (GLP)-1 receptor agonists which must have been stable for ≥3 months (except for weekly GLP-1 receptor agonists which must have been stable for ≥4 months)

  • Participant must not have type 1 diabetes mellitus (T1DM) or other types of diabetes mellitus

  • Participant must not have known hypersensitivities or allergies to insulin

  • Participant must not have used U-500R within 3 months prior to screening

  • Participant must not have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia

Where This Study Took Place Tool Tip Icon

1 location participated
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.